**Policy Summary: Nanotechnology-Based Early Detection of Parkinson's Disease**
The Ministry of Science and Technology highlights a significant advancement in the early detection of Parkinson's Disease (PD) through nanotechnology. Researchers at the Institute of Nano Science and Technology (INST), Mohali, an autonomous institute of the Department of Science and Technology (DST), have developed a novel biosensor utilizing gold nanoclusters (AuNCs) to differentiate between normal and toxic forms of the synuclein protein, a key indicator of PD.
The biosensor employs amino acid-coated AuNCs, with proline-coated clusters targeting the normal protein form and histidine-coated clusters binding to toxic aggregates. This selective binding allows for the distinction between harmless monomeric synuclein and toxic amyloid forms.
The research methodology involved engineering and purifying normal and mutant synuclein proteins, synthesizing and characterizing amino acid-capped AuNCs using techniques such as UV-Vis spectroscopy, fluorescence imaging, transmission electron microscopy (TEM), and X-ray photoelectron spectroscopy (XPS). The interaction between nanoclusters and proteins were studied through gel electrophoresis, fluorescence quenching, and electrochemical methods like cyclic voltammetry and impedance spectroscopy. The system's efficacy and safety were validated in human-derived SHSY5Y neuroblastoma cells.
The research team was led by Dr. Sharmistha Sinha, Senior Scientist at INST, with contributions from PhD students Ms. Harpreet Kaur and Ms. Ishani Sharma, in collaboration with Dr. Deepak Sharma and Arpit Tyagi at CSIR-Institute of Microbial Technology (IMTECH), Chandigarh.
The development of this labelfree, low-cost, and clinically adaptable biosensor holds the potential for earlier PD diagnosis, improved patient outcomes, reduced healthcare costs, and potential application in detecting other diseases linked to misfolded proteins, such as Alzheimer's disease. The study has been accepted for publication in the journal *Nanoscale*, Royal Society of Chemistry. Release ID: 2160886.
Key Entities Referenced
Parkinsons Disease: A neurological disorder that is the focus of early detection research using nanotechnology.
Ministry of Science Technology: The Indian government ministry under which the research was conducted.
Institute of Nano Science and Technology INST, Mohali: An autonomous institute of the Department of Science and Technology (DST) where the research was conducted. Mohali is a city in Punjab, India.
Department of Science and Technology DST: The department under which INST functions.
synuclein: A protein linked to Parkinsons Disease, studied for its role in early detection.
Alzheimers: A disease linked to misfolded proteins, mentioned as a potential application for similar nanotechnology.
CSIRInstitute of Microbial Technology IMTECH, Chandigarh: An institute collaborating on the project, providing expertise in protein biochemistry and cell-based assays. Chandigarh is a city in India and a union territory.
Dr. Sharmistha Sinha: Senior Scientist at INST, leading the project.
Ministry of Science & Technology
Tiny Gold Particles can help early detection of
Parkinson’s Disease
Posted On: 26 AUG 2025 4:52PM by PIB Delhi
The yellow metal, rather tiny particles of it, can hold the key to a nanotechnology-based tool for
early detection of Parkinson’s Disease (PD).
Parkinson’s disease is one of the fastest-growing neurological disorder globally. With an aging population and
rising life expectancy, the number affected by the disease in India is projected to increase substantially,
placing immense pressure on healthcare systems. Yet, most diagnoses occur only after significant
neurodegeneration has already taken place.
Hence researchers are on the lookout for ways in which the disease can be detected at an early stage so that
adequate measures can be taken to manage it appropriately.
A group discussion among scientists at Institute of Nano Science and Technology (INST), Mohali an
autonomous institute of the Department of Science and Technology (DST) exploring how proteins behave
differently in the brain during disease, sparked a big idea. They started exploring whether they could detect
how dangerous a protein is just by sensing its surface charge.
They focused their attention on a protein called -synuclein linked to PD. This protein changes
shape, starting out harmless, and eventually clumping into toxic forms that damage brain cells. The
team started working towards a sensor to tell these protein forms apart, just by how they’re
charged.
Fig: Gold nanocluster-based biosensor distinguishes between physiological and pathological α-synuclein
conformers, enabling early-stage detection of Parkinson’s disease.Their solution came in the form of gold nanoclusters (AuNCs), ultrasmall, glowing particles just a
few nanometers wide. By coating these nanoclusters with naturally occurring amino acids, the
researchers gave them selective “stickiness.” Proline-coated clusters were drawn to the normal
version of the protein, while histidine-coated ones latched onto the toxic aggregates. This helped
distinguish between the harmless monomeric form and the toxic aggregated (amyloid) form.
The journey from concept to proof-of-principle involved a broad spectrum of experiments. The team began by
engineering and purifying two forms of the α-synuclein protein (normal and mutant). They then synthesized
the amino acid–capped gold nanoclusters and meticulously characterized them using high-end techniques
such as UV-Vis spectroscopy, fluorescence imaging, electron microscopy (TEM), and X-ray photoelectron
spectroscopy (XPS) to understand their optical and structural properties. The interactions between
nanoclusters and proteins were studied through gel electrophoresis, fluorescence quenching, and
electrochemical methods like cyclic voltammetry and impedance spectroscopy, which allowed the team to
measure how sensitively the nanoclusters could detect different forms of the protein. Finally, the system was
tested in human-derived SH-SY5Y neuroblastoma cells to ensure it worked safely and effectively in
biological conditions.
The project was led by Dr. Sharmistha Sinha, Senior Scientist at INST, and was supported by her
PhD students Ms. Harpreet Kaur and Ms. Ishani Sharma. They also collaborated with Dr. Deepak
Sharma and Arpit Tyagi at CSIR-Institute of Microbial Technology (IMTECH), Chandigarh, who
contributed their expertise in protein biochemistry and cell-based assays. This collaboration
between young researchers and experienced scientists helped turn a simple lab discussion into a
validated biosensing platform.
A tool that can detect the disease before symptoms appear could mean earlier treatment, improved
quality of life, and lower long-term healthcare costs.
The research also opens the door to detecting other diseases linked to misfolded proteins, like Alzheimer’s,
using similar nanotechnology. By making the system label-free, low-cost, and clinically adaptable, the team
hopes it can someday be used in point-of-care testing—bringing powerful diagnostics closer to people who
need them most. It could contribute to the global effort to prevent and manage non-communicable
neurological diseases.
The study has just been accepted at the journal Nanoscale (Royal Society of Chemistry).
***
NKR/PSM
(Release ID: 2160886)